{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T08:10:39Z","timestamp":1782547839800,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s10637-023-01366-3","type":"journal-article","created":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T02:02:28Z","timestamp":1683856948000},"page":"512-521","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis"],"prefix":"10.1007","volume":"41","author":[{"given":"Takafumi","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Kanamori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Toyoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsunari","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Sone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatoshi","family":"Ishigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,12]]},"reference":[{"issue":"1","key":"1366_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/hep.31227","volume":"72","author":"T Peeraphatdit","year":"2020","unstructured":"Peeraphatdit T, Wang J, Odenwald MA et al (2020) Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation. Hepatology 72(1):315\u201329","journal-title":"Hepatology."},{"key":"1366_CR2","doi-asserted-by":"crossref","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade.\u00a0N Engl J Med 378(2):158\u2013168","DOI":"10.1056\/NEJMra1703481"},{"issue":"4","key":"1366_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F et al (2020) Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance. Target Oncol. 15(4):449\u201366","journal-title":"Target Oncol."},{"issue":"6","key":"1366_CR4","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cllc.2019.07.006","volume":"20","author":"J Fukihara","year":"2019","unstructured":"Fukihara J, Sakamoto K, Koyama J et al (2019) Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non\u2013Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors. Clin Lung Cancer. 20(6):442-450.e4","journal-title":"Clin Lung Cancer."},{"issue":"2","key":"1366_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/07357907.2021.1994586","volume":"40","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto T, Ito T, Hase T et al (2021) Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. Cancer Invest. 40(2):189\u201398","journal-title":"Cancer Invest."},{"key":"1366_CR6","doi-asserted-by":"crossref","unstructured":"Mizuno K, Ito T, Ishigami M et al (2020) Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies.\u00a0J Gastroenterol\u00a055(6):653\u2013661","DOI":"10.1007\/s00535-020-01677-9"},{"key":"1366_CR7","doi-asserted-by":"crossref","unstructured":"Ito T, Ishigami M, Yamamoto T et al (2021) Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies.\u00a0Hepatol Int 15(5):1278\u20131287","DOI":"10.1007\/s12072-021-10238-y"},{"key":"1366_CR8","doi-asserted-by":"crossref","unstructured":"De Martin E, Michot JM, Papouin B et al (2018) Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.\u00a0J Hepatol 68(6):1181\u20131190","DOI":"10.1016\/j.jhep.2018.01.033"},{"key":"1366_CR9","doi-asserted-by":"crossref","unstructured":"Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.\u00a0Invest New Drugs 35(4):529\u2013536","DOI":"10.1007\/s10637-017-0453-0"},{"key":"1366_CR10","doi-asserted-by":"crossref","unstructured":"Gelsomino F, Vitale G, Ardizzoni A (2018) A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.\u00a0Invest New Drugs 36(1):144\u2013146","DOI":"10.1007\/s10637-017-0484-6"},{"key":"1366_CR11","doi-asserted-by":"crossref","unstructured":"Onoyama T, Takeda Y, Yamashita T et al (2020) Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review.\u00a0World J Gastroenterol 26(8):353\u2013365","DOI":"10.3748\/wjg.v26.i3.353"},{"key":"1366_CR12","doi-asserted-by":"crossref","unstructured":"Kashima J, Okuma Y, Shimizuguchi R et al (2018) Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.\u00a0Cancer Immunol Immunother 67(1):61\u201365","DOI":"10.1007\/s00262-017-2062-3"},{"key":"1366_CR13","doi-asserted-by":"crossref","unstructured":"Cheung V, Gupta T, Payne M et al (2019) Immunotherapy-related hepatitis: real-world experience from a tertiary centre.\u00a0Frontline Gastroenterol 10(4):364\u2013371","DOI":"10.1136\/flgastro-2018-101146"},{"key":"1366_CR14","doi-asserted-by":"crossref","unstructured":"Andrade RJ, Aithal GP, Bj\u00f6rnsson ES et al (2019) EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol 70(6):1222\u20131261","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"1366_CR15","doi-asserted-by":"crossref","unstructured":"Aithal GP, Watkins PB, Andrade RJ et al (2011) Case definition and phenotype standardization in drug-induced liver injury.\u00a0Clin Pharmacol Ther 89(6):806\u2013815","DOI":"10.1038\/clpt.2011.58"},{"key":"1366_CR16","doi-asserted-by":"crossref","unstructured":"De Martin E, Michot JM, Rosmorduc O et al (2020) Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors.\u00a0JHEP Reports Innov Hepatol 2(6)","DOI":"10.1016\/j.jhepr.2020.100170"},{"key":"1366_CR17","doi-asserted-by":"crossref","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics.\u00a0Bone Marrow Transplant 48(3):452\u201358","DOI":"10.1038\/bmt.2012.244"},{"key":"1366_CR18","doi-asserted-by":"publisher","unstructured":"Berry P, Kotha S, Zen Y et al (2022) Immune checkpoint inhibitor-related cholangiopathy: Novel clinicopathological description of a multi-centre cohort.\u00a0Liver Int. https:\/\/doi.org\/10.1111\/liv.15340. Online ahead of print","DOI":"10.1111\/liv.15340"},{"key":"1366_CR19","doi-asserted-by":"crossref","unstructured":"Takinami M, Ono A, Kawabata T et al (2021) Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.\u00a0Invest New Drugs 39(6):1716\u20131723","DOI":"10.1007\/s10637-021-01136-z"},{"key":"1366_CR20","doi-asserted-by":"crossref","unstructured":"Koya Y, Shibata M, Shinohara N et al (2019) Secondary sclerosing cholangitis with hemobilia induced by pembrolizumab: Case report and review of published work. Hepatol Res 49(8):950\u2013956","DOI":"10.1111\/hepr.13329"},{"key":"1366_CR21","doi-asserted-by":"crossref","unstructured":"Hori H, Fujita K, Nishio A et al (2022) Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature. Clin J Gastroenterol 15(2):475\u2013479","DOI":"10.1007\/s12328-022-01593-w"},{"key":"1366_CR22","doi-asserted-by":"crossref","unstructured":"Husain B, Kirchberger MC, Erdmann M et al (2021) Inflammatory markers in autoimmunity induced by checkpoint inhibitors.\u00a0J Cancer Res Clin Oncol 147(6):1623\u20131630","DOI":"10.1007\/s00432-021-03550-5"},{"key":"1366_CR23","doi-asserted-by":"crossref","unstructured":"Abolhassani AR, Schuler G, Kirchberger MC et al (2019) C-reactive protein as an early marker of immune-related adverse events.\u00a0J Cancer Res Clin Oncol 145(10):2625\u20132631","DOI":"10.1007\/s00432-019-03002-1"},{"key":"1366_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.906824","volume":"12","author":"Y Yu","year":"2022","unstructured":"Yu Y, Wang S, Su N et al (2022) Increased Circulating Levels of CRP and IL-6 and Decreased Frequencies of T and B Lymphocyte Subsets Are Associated With Immune-Related Adverse Events During Combination Therapy With PD-1 Inhibitors for Liver Cancer. Front Oncol. 12","journal-title":"Front Oncol."},{"key":"1366_CR25","doi-asserted-by":"crossref","unstructured":"Heinrich PC, Castell J V., Andus T (1990) Interleukin-6 and the acute phase response.\u00a0Biochem J 265(3):621\u2013636","DOI":"10.1042\/bj2650621"},{"key":"1366_CR26","doi-asserted-by":"crossref","unstructured":"Dimitriou F, Hogan S, Menzies AM et al (2021) Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.\u00a0Eur J Cancer 157:214\u2013224","DOI":"10.1016\/j.ejca.2021.08.031"},{"key":"1366_CR27","doi-asserted-by":"crossref","unstructured":"Moi L, Bouchaab H, Mederos N et al (2021) Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.\u00a0J Thorac Oncol 16(2):318\u2013326","DOI":"10.1016\/j.jtho.2020.09.007"},{"issue":"5","key":"1366_CR28","first-page":"763","volume":"10","author":"R Nakano","year":"2022","unstructured":"Nakano R, Shiomi H, Fujiwara A et al (2022) Clinical Characteristics of ICI-Related Pancreatitis and Cholangitis Including Radiographic and Endoscopic Findings. Healthc (Basel, Switzerland). 10(5):763","journal-title":"Healthc (Basel, Switzerland)."},{"key":"1366_CR29","doi-asserted-by":"crossref","unstructured":"Pi B, Wang J, Tong Y et al (2021) Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management.\u00a0Eur J Gastroenterol Hepatol 33(1S Suppl 1):e858\u2013e867","DOI":"10.1097\/MEG.0000000000002280"},{"key":"1366_CR30","doi-asserted-by":"crossref","unstructured":"Yamamoto T, Ito T, Mizuno K et al (2022) A case of antiprogrammed death-ligand 1 antibody-induced multisystem immune-related adverse events with pancreatitis and steroid-resistant sclerosing cholangitis.\u00a0J Dig Dis 23(7):404\u2013409","DOI":"10.1111\/1751-2980.13122"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01366-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-023-01366-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-023-01366-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T17:37:38Z","timestamp":1687541858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-023-01366-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,12]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1366"],"URL":"https:\/\/doi.org\/10.1007\/s10637-023-01366-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2783140\/v1","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,12]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted by the tenets of the Declaration of Helsinki and approved by the Institutional Review Board of Nagoya University Hospital (no. 2018-0438).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Approval of the research protocol"}},{"value":"Informed consent for this study was obtained from the website of Nagoya University Hospital.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}},{"value":"N\/A.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Registry and the registration no. of the study\/trial"}},{"value":"N\/A.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Animal studies"}},{"value":"N\/A.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving recombinant DNA"}},{"value":"Takanori Ito received personal fees from Chugai Pharmaceutical Co., Ltd. outside the submitted work. Masatoshi Ishigami received grants from Chugai Pharmaceutical Co., Ltd. outside the submitted work. Tetsunari Hase received grants and personal fees from AstraZeneca, grants and personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Bristol-Myers Squibb Co., and personal fees from MSD K.K, outside the submitted work. Yuichi Ando received grants and personal fees from Chugai Pharmaceutical Co.,Ltd., grants and personal fees from Kyowa Kirin Co.,Ltd., grants and personal fees from Nippon Kayaku Co., Ltd., grants and personal fees from Yakult Honsha Co.,Ltd., personal fees from Eli Lilly Japan K.K., grants and personal fees from Ono Pharmaceutical Co.,Ltd., grants and personal fees from Taiho Pharmaceutical Co.,Ltd., grants and personal fees from Novartis Pharma K.K., personal fees from Bayer Holding Ltd., personal fees from Sawai Pharmaceutical Co., Ltd, grants and personal fees from Daiichi Sankyo Company, Ltd., grants and personal fees from Eisai Co.,Ltd., personal fees from MSD K.K, personal fees from Astellas Pharma Inc., personal fees from Otsuka Holdings Co.,Ltd., personal fees from Sanwa Kagaku Kenkyusho Co., Ltd., personal fees from Hisamitsu Pharmaceutical Co., Inc., personal fees from SymBio Pharceuticals, personal fees from Aptitude Health, grants from BeiGene, Ltd, personal fees from Alfresa Pharma Corporation, outside the submitted work; . Masashi Akiyama received research grants from Ono Pharmaceutical Co., Ltd. and Taiho Pharmaceutical Co., Ltd. outside the submitted work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest disclosure"}}]}}